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Abstract:  
Pharmacotherapy as an adjunct to behaviour modification, may provide an 
effective addition to individual weight management plans in specialised weight 
management services. There are four FDA approved centrally acting weight-
loss drugs (liraglutide, bupropion/naltrexone, lorcaserin, 
phentermine/topiramate), and several additional candidate drugs yet to receive 
approval. Each drug has a distinct pharmacological mechanism of action, and 
presumably will support eating behaviour modification in different ways. Here, 
we assess to what extent behavioural mechanisms of action have been 
characterised. We recommend a methodological platform to be introduced pre-
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approval in order to achieve principal objectives of phase II and III trials 
(demonstrate efficacy), and afford stratification of responders to treatment, by 
behavioural and neurophysiological response. 
Keywords: obesity; pharmacotherapy 
Introduction: 
Obesity has now reached pandemic status across the developed and developing 
world (WHO, 2018). The escalating health, social, and economic impacts of this 
means that there is a pressing need for safe and effective treatments. 
Pharmacotherapy may be one method to provide much needed assistance for 
patients to make the necessary behaviour modification to achieve meaningful 
weight loss. There is potential for a variety of weight-loss drugs to be used in 
specialist weight management services, each to be tailored to patient’s 
individual needs. However currently not enough is being done to characterise 
responders to drug treatment, or fully appreciate drug effects on the minutiae of 
appetite expression, indeed it is notable that there is a huge variation in clinical 
response to drug therapy.  In this review we discuss the mechanistic data 
available for the currently approved anti-obesity drugs, and the potential 
behavioural action of candidate drugs. We suggest that a behavioural and 
neuroimaging experimental platform should be utilised earlier in the drug 
approval process to assess how novel candidate weight-loss drugs will work on 
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a behavioural level enabling accurate identification on who the will benefit the 
most. 
Behaviour change: 
Behaviour modification is the cornerstone of obesity management (Jensen et al., 
2014). Changes in eating behaviour are necessary to reduce energy intake, and it 
is preferential for daily activity to be increased in order to expend more energy. 
However, making the necessary changes to eating behaviour is extremely 
difficult for many people. Individuals with obesity commonly have a biological 
vulnerability for overconsumption which is expressed in behaviours that 
comprise a susceptible behavioural phenotype for obesity (Blundell et al., 
2005). Our (neuro)biological differences underpin our experienced differences 
in satiety (feelings of hunger, and fullness), food-reward (pleasure/enjoyment of 
eating, food craving, and ability of food to grab our attention), and ability to 
exert inhibitory control (stop ourselves from eating beyond our energetic needs) 
over our behaviour. In addition to this, behaviour is shaped by life-long 
learning, and change requires tackling habits that have become entrenched. 
Difficulties in adhering to behaviour change is further compounded by the fact 
that energy restriction causes increases in hunger, dysphoria, increased 
motivation to eat, and distraction by, and preoccupation with food. Taken 
together, this means that behaviour modification requires constant exertion in 
people who are already biologically predisposed to overeat.  
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Personalised approach: 
A biopsychosocial approach to personalised weight management strategies 
includes utility of psychological interventions, pharmacotherapy, and if 
necessary bariatric surgery (Castelnuovo et al., 2017). Pharmacotherapy, as an 
adjunct to behaviour modification, may provide an effective addition to 
individual weight management plans in specialised weight management services 
if used correctly. Critically, if we wish to use weight-loss drugs as part of a 
personalised intervention, it is necessary to understand individual differences in 
patient experiences and their personal barriers to behaviour change, as well as 
how a drug therapy may impact the particular behaviours the patient exhibits. 
To achieve this, the behavioural mechanism of action of a drug needs to be 
characterised, and effectively communicated to patients and practitioners before 
implementing as part of a suite of personalised weight-management strategies. 
Currently approved drugs (EMA and or FDA approval) 
There are currently 2 EMA, and a further 2 FDA approved centrally acting 
medications for weight loss. Each of these drugs has a different 
pharmacological mechanism of action (see table 1 and figure 1), meaning that 
they ostensibly have a distinct behavioural mechanism of action, and act 
differently at important neural networks associated with satiety, reward and 
inhibitory control.  
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Liraglutide 3mg (Saxenda):  The GLP-1 receptor agonist Liraglutide is 
approved for weight-loss by both the EMA and FDA at the 3.0mg injectable 
dose, due to it demonstrating efficacy of achieving weight loss in the Satiety 
and Clinical Adiposity-Liraglutide Evidence (SCALE) studies (Davies et al., 
2015: Wadden et al., 2013; Blackmore et al., 2016). However mechanistic data 
are limited to one study with the approved 3.0mg dose (van Can et al., 2014), 
which showed liraglutide (3.0 and 1.8) reduced food intake at an ad-libitum 
lunch meal by 16% compared to placebo. Liraglutide increased post-meal 
satiety, and fullness ratings, and reduced prospective consumption. The 
proposed behavioural mechanism by which liraglutide 3.0mg produces weight-
loss is by boosting satiety. However no other mechanistic data exist at the 
approved dose. Drug effects on hedonic aspects of eating and inhibitory control 
have yet to be tested, nor is there neuroimaging data available at this dose. 
Responders to liraglutide 3.0mg for weight-loss have yet to be properly 
characterised. Our mechanistic understanding of how this drug works primarily 
comes from data with the 1.8mg dose in diabetic populations (see Roberts et al., 
2017 for review). 
Lorcaserin: An FDA approved 5-HT2c receptor agonist. Patients have been 
shown to have higher chance of achieving 5% weight loss with lorcaserin 
compared to placebo in a number of weight-loss trials in obese populations 
(Smith et al., 2010; O’Neil et al., 2012; Fidler et al., 2011; although the weight 
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loss associated with lorcaserin is argued to be modest (Roberts & Halford, 
2018). However, lorcaserin has demonstrable cardiovascular safety, as reported 
by Bohula et al. (2018) and patients can be maintained on lorcaserin for over 3 
years without increased incidence of cardiovascular problems. Lorcaserin has 
affinity for the 5HT2C receptor subtype, which belies the improved safety profile 
relative to previous (withdrawn) serotonergic drugs with affinities of the 2A and 
2B receptor subtypes (sibutramine, fenfluramine). 
There is more mechanistic data for lorcaserin than other approved drugs, 
however complete behavioural and neurophysiological characterisation is 
elusive. Martin et al. (2010) report reduced energy intake at lunch and dinner 
ad-libitum buffet meals compared to placebo, and decreased hunger ratings, but 
no effects on food cravings, or dietary restraint or disinhibition. Farr et al. 
(2016) measured neuronal activity in response to viewing food images in 
patients receiving lorcaserin and placebo. Lorcaserin reduced parietal cortex 
activity in response to food images relative to non-food images, which the 
authors suggest may reflect reduced motivational responses to foods. Although, 
Inhibitory control (measured outside of the scanner) was unaffected by 
lorcaserin. This study is of particular interest due to its novel use of baseline 
fMRI activity to predict responders to lorcaserin treatment. The authors report 
that amygdala and occipital activation in response to highly palatable food 
predicted reduced BMI at 4 weeks of treatment. 
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Chao et al. (2018) included subjective measures of food craving, emotion, and 
stress related eating, binge eating, cognitive restraint, disinhibition, 
preoccupation with eating and fullness, in patients given either lorcaserin or 
placebo during a weight maintenance period immediately following successful 
5% weight-loss. During this period lorcaserin treated patients had improved 
emotion and reductions in stress related eating, but no effects were observed in 
any other subjective measures relating to eating behaviour.  
The totality of the data suggest that lorcaserin has modest effects on satiety, but 
may be useful for patients with cardiovascular problems, emotional eaters, or 
those who are highly responsive to palatable foods. However, confirmatory 
subjective and behavioural data are needed to elucidate this. 
Bupropion/naltrexone: This is a combination drug of a catecholamine reuptake 
inhibitor (bupropion) and opioid receptor antagonist (naltrexone) which is both 
FDA and EMA approved. Several phase III trials have demonstrated improved 
odds of achieving 5% weight loss with bupropion/naltrexone compared to 
placebo (Greenway et al., 2010; Wadden et al., 2011). However, there are no 
clinical experimental data showing how bupropion/naltrexone modifies eating 
behaviour. There is a narrative that this drug improves inhibitory control (an 
effect we suggest could be mediated by drug action on dopaminergic activity in 
prefrontal cortex – see fig. 1), and patient’s ability to resist cravings which is 
based on an fMRI study suggesting bupropion/naltrexone increases anterior 
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cingulate activity (Wang et al., 2014). The anterior cingulate is an important 
brain region involved in inhibitory control, however the observed activity was 
not in relation to an inhibitory control task, so there are no corollary behavioural 
data. A more recent resting state fMRI study (Wang et al., 2018) suggests 
bupropion/naltrexone increases functional connectivity between areas of the 
parietal cortex, insula and anterior cingulate, which may underpin improved 
inhibitory control. This study also observed reduced functional connectivity in 
the medial prefrontal cortex – an area implicated in craving. Overall we have 
some very interesting fMRI data with this drug, however we are still some 
distance from properly characterising how drug treatment manifests 
behaviourally.  
Phentermine/topiramate: This combination of the noradrenaline (and 
dopamine) releasing agent phentermine and GABAergic topiramate has FDA 
approval only. There are several studies demonstrating its efficacy for achieving 
at least 5% weight loss (Gadde et al., 2011; Li et al., 2016; Allison et al., 2012). 
Despite meta-analysis of phase III weight loss trials suggesting this drug 
combination produces the greatest odds of achieving 5% weight-loss of all the 
approved weight-loss drugs, there are no mechanistic data available to 
demonstrate proof of concept for behaviour modification (potential behavioural 
mechanism of action outlined in figure 1). 
AC
CE
PT
ED
 M
AN
US
CR
IPT
A comprehensive Bayesian network meta-analysis (Khera et al., 2016) has been 
performed on pooled data from all of the phase III weight-loss studies with each 
of the FDA/EMA approved anti-obesity medications. A median of 75% 
participants achieved 5% weight loss with phentermine/topiramate. This 
number was 63% with liraglutide 3.0mg, 55% with bupropion/naltrexone, and 
49% with lorcaserin. Results from these meta-analyses suggest that there is 
clearly a large portion of the wider population that may not respond each 
treatment option (Roberts & Halford, 2018). It is increasingly clear that weight-
loss trials alone are no longer adequate to address efficacy of these drugs. 
Rather, complete characterisation of the behavioural and neurophysiological 
manifestation of taking these drugs is necessary to improve efficacy of drug 
treatment, and optimise their tailored intervention potential.  
Novel candidate drugs on the horizon 
There are currently several novel candidate drugs for weight-loss which may 
modify behaviour. These are at different stages the approval process, their 
pharmacological and putative behavioural mechanism of action is summarised 
below (see also figure 1). 
Setmelanotide: This is a synthetic MC4R-agonist, which increases energy 
expenditure in preclinical studies (Kievit et al., 2013). Phase I studies in humans 
also suggest increased resting energy expenditure (Chen et al., 2015). As 
setmelanotide acts on MC4 receptors, this may have an effects on satiety, which 
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could be expressed as reduced meal intake and rate of eating. This drug is being 
investigated for treatment of rare genetic disorders of obesity, such as Prader-
Willi syndrome (Srivastave & Apovian, 2018). 
Zonisamide-Bupropion: This combination therapy combines Zonisamide which 
is pharmacologically complex antiepileptic drug with action at sodium channels, 
as well as dopamine and serotonin activity. It is combined with the atypical anti-
depressant bupropion. Combined, this drug targets 3 major neurotransmitters in 
regulation of appetite (serotonin, dopamine, and norepinipherine), so may 
modify regulatory components of eating behaviour (Gadde et al., 2007). 
Zonasimide-bupropion have completed plase II clinical trials with 60.4% of 
patients achieving 5% weight loss in 24 weeks (Srivastave & Apovian, 2018). 
Semaglutide: Semaglutide is an extended release formulation of liraglutide 
which is currently undergoing phase II weight-loss trials for obesity 
management. Interestingly some behavioural characterisation has begun in 
phase II. Blundell et al. (2017) has assessed energy intake at ad-libitum meals 
across the day, subjective fluctuations in satiety, fullness, hunger and 
prospective consumption across the day, palatability (food reward), and food 
preference, energy expenditure and subjective measures of control of eating. 
Semaglutide reduced energy intake across the day (24% total reduction relative 
to placebo), reduced hunger, food cravings and increased subjective feelings of 
control of eating, with lower preference for high-fat foods.  
AC
CE
PT
ED
 M
AN
US
CR
IPT
The case for a methodological platform for assessing drug action to be 
implemented pre-approval. 
Currently, if any mechanistic data is conducted to observe how drugs produce 
weight loss, this is conducted in phase IV, post-approval, clinical trials. 
Moreover, as demonstrated in this review mechanistic data is being conducted 
piece-meal, in an uncoordinated manner, often on subjective rather than 
objective measures, meaning that our understanding of drug effects has to be 
reconstructed from datasets across studies. In our 2017 paper (Roberts et al., 
2017) we proposed a novel methodological platform to investigate the interplay 
between satiety, reward, and inhibitory control using a comprehensive test 
battery of validated measures for assessing eating behaviour, subjective 
experiences of appetite regulation, and neurophysiological effects. Using this 
platform across studies would allow 1) characterisation of drug effects on the 
interaction of the full range of mechanisms which control eating behaviour, 2) 
proof-of-concept data linking pharmacological mechanism of action to human 
appetite expression 3) stratification of responders to treatment, by behavioural 
and neurophysiological response 4) allow effective communication to patients 
and practitioners of real world benefits of tailored pharmacotherapy 5) effective 
testing of novel candidate drugs at an earlier stage than phase IV clinical trials.  
Principal objectives of phase II and phase III clinical trials are to demonstrate 
effectiveness of a new medicine to treating a condition (Fig 2). Given the 
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importance of behaviour, and neurocognition in the aetiology of obesity, it is 
our opinion that weight-loss studies are inadequate in fulfilling the basic 
objectives of phase II and phase III studies. Our experimental medicine 
approach can be used in phase II and III clinical trials with novel compounds to 
demonstrate effectiveness of new medicines to modify eating behaviour in order 
to produce meaningful weight-loss, and to enable predictions of responders. 
Using this platform would not only provide consistency for interpretation of 
effects across drugs, but it would also add value to phase III clinical trial data, 
enabling pharmaceutical companies to demonstrate cost-effectiveness of their 
drug for specific treatment populations.  
In addition to the measures outlined in our methodological platform, the 
Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) project 
(MacLean et al., 2018) have also proposed several core measures that should be 
considered for use in obesity trials. Beyond eating behaviour ADOPT propose 
core measures in other behavioural, biological, environmental, and psychosocial 
domains with a view to accumulate data on individual variability in response to 
various obesity treatment options, in order to inform personalisation of obesity 
treatment. 
In conclusion, it is clear that response to any weight-loss treatment will have 
large individual variability. Therefore conducting the necessary mechanistic 
assessments, in a consistent and coordinated manner will increase the likelihood 
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of effective use of anti-obesity drugs in our attempts to reduce current pandemic 
levels of obesity.  
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Fig 1. Proposed mechanisms of action of approved and candidate weight loss 
drugs.  
1) Lorcaserin stimulates 5-HT receptor subtype 2C in arcuate nucleus of 
hypothalamus which is proposed to boost satiety 
2) Bupropion/Naltrexone: Bupropion stimulates POMC neuron to produce 
MC4R agonist αMSH. Naltrexone antagonises opioid receptors on 
POMC to prevent auto-inhibition of POMC following bupropion 
stimulation. Naltrexone also antagonises opioid receptors in hedonic 
hotspots of nucleus accumbens, reducing reward (liking). Bupropion 
blocks reuptake of dopamine, which in the PFC may improve inhibitory 
control. 
3) Liraglutide and Semaglutide both stimulate GLP1 receptors located in 
arcuate nucleus of hypothalamus which increases satiety. Moreover GLP1 
receptor agonism in the nucleus accumbens reduces liking. 
4) Phentermine/Topiramate: Topiramate stimulates GABA release which has 
an inhibitory effect of NPY/AGRP, and so reduceds feelings of hunger 
normally precipitated by stimulation here. Phentermine stimulates 
noradrenalin release from the hypothalamus, which increases satiety. 
Phentermine also has an effect on dopamine, which in the PFC may 
improve inhibitory control. 
5) Setmelanotide is an agonist at the MC4R which increases satiety. 
6) Zonisamide/Bupropion. Zonisimide stimulates serotonin, dopamine, and 
has effects at sodium channels. Bupropion action is outlined above. 
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 Figure 2. The four clinical trial phases for a new medicinal product. We argue 
that behavioural and neurophysiological assessment are required at phase II and 
III trials with weight-loss drugs to properly achieve the primary objectives. 
Meaning, to assess/demonstrate efficacy of drug for treating the condition. 
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Table 1: Current approved drugs (EMA and/or FDA) for weight loss, pharmacological mechanism of action, effects on 
eating behaviour, and CNS activity. 
Drug Approval  Pharmacological 
mechanism of action 
 Satiety Reward IC Neuronal 
activity 
Liraglutide 3mg EMA, 
FDA 
GLP-1 receptor 
agonist 
 Reduced 
ad-lib meal 
intake. 
Increased 
post-meal 
satiety 
No data No data No data 
        
Lorcaserin FDA Selective 5HT2C 
receptor agonist 
 Reduced 
intake. 
Decreased 
hunger 
No effects 
on 
cravings. 
No 
behavioural 
data 
No effect on 
inhibitory 
control 
performance 
Reduced 
activity in 
parietal cortex 
in response to 
food images 
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Bupropion/naltrexone EMA, 
FDA 
Combination of a 
dopamine/noradrenalin 
reuptake inhibitor + 
opioid receptor 
antagonist 
 No 
behavioural 
data 
No 
behavioural 
data 
No 
behavioural 
data 
Reduced 
anterior 
cingulate 
activity 
(passive 
viewing of 
food images). 
Reduced 
functional 
connectivity 
between  
parietal 
cortex, insula 
and anterior 
cingulate 
(resting state 
fMRI). 
        
 
Phentermine/topiramate 
 
FDA 
 
TAAR1 agonist and 
noradrenalin releasing 
agent + sulfamate-
  
No data 
 
No data 
 
No data 
 
 
No data 
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substituted 
monosaccharide with 
action on GABA 
signalling 
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